First patient treated in Clarity’s Cu-64 SAR-bisPSMA prostate cancer trial
Sydney, Australia 10 August 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been dosed in the 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer. Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very excited to…